March 18, 20248:30 AM - 4:00 PM ET
Join us for the highly anticipated and dynamic IAS–USA annual course in New York, New York, for the most current and clinically relevant information in HIV care. Don’t miss out on the opportunity to engage with faculty and peers in person and to stay at the forefront of what’s new in HIV management. This live course will be in person at the NYU Skirball Center, and there will NOT be a simultaneous virtual component for this course.
This in-person course will focus on recent advances in HIV medicine, including updates from Conference on Retroviruses and Opportunistic Infections (CROI) 2024; new antiretroviral formulations and strategies, management of substance use disorder (SUD) in people with HIV; sexually transmitted infections (STIs) prevention, including current epidemiology in the US; update in the treatment implications of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) trial in people with HIV; review of the current state and understanding of long-acting drugs for the treatment and prevention of HIV; challenges of hypertension and cardiometabolic complications associated with antiretroviral therapy; and a case-based panel discussion on antiretroviral therapy. This course will also highlight the emerging data around the use of glucagon-like peptide 1 (GLP-1) agonists drugs among individuals with HIV, including diabetes, weight loss, potential treatment for addictions, comorbidities, and explore other ongoing research on their use.
We remain committed to closely monitoring the evolving state of the pandemic. We will ensure that our vaccination policy and mask guidelines align with the circumstances leading up to the course.
Assessment of Needs
Rapid advances in HIV disease management require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.
After participating in the activity, learners will be able to:
- Implement the latest recommendations for initiating and changing antiretroviral therapy in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
- Describe the most current data from recent HIV scientific conferences, including research on new and investigational antiretroviral drugs
- Describe the current epidemiology, clinical presentation, prevention, and management of relevant common sexually transmitted infections (STIs) in adults with HIV
- Manage substance use disorders, including opioids, stimulants, and alcohol in people with HIV
- Integrate findings from the REPRIEVE trial into the treatment plans for adults with HIV
- Describe the current research of GLP-1 agonist therapy for people with HIV
- Identify the challenges of hypertension and cardiometabolic complications in people on antiretroviral therapy
- Key Updates from CROI 2024
- Substance use disorder management in people with HIV
- Update on the treatment implications of REPRIEVE
- What’s new in STI management, including doxyPEP, and vaccines
- Managing hypertension and cardiometabolic complications associated in people on antiretroviral therapy
- Challenges in implementing long-acting drugs for treatment and prevention of HIV
- GLP-1 agonist therapy for people with HIV
Conflicts of Interest
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.
Who Should Attend
This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for patients with HIV infection
- Are currently active in HIV research
This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.
Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.
Cancellation requests must be made 14 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.
Educational Review Systems is an approved approver of continuing nursing education by the ASNA, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 6 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692), the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 6 contact hours (0.6 CEUs) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-24-032-L02-P
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co, Inc.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at email@example.com or 415-544-9400.